PortfoliosLab logo

Arcutis Biotherapeutics, Inc. (ARQT)

Equity · Currency in USD · Last updated Mar 26, 2023

Share Price Chart


Loading data...

Performance

The chart shows the growth of $10,000 invested in Arcutis Biotherapeutics, Inc. in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $4,693 for a total return of roughly -53.07%. All prices are adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%NovemberDecember2023FebruaryMarch
-53.07%
23.11%
ARQT (Arcutis Biotherapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ARQT

Arcutis Biotherapeutics, Inc.

Return

Arcutis Biotherapeutics, Inc. had a return of -30.88% year-to-date (YTD) and -41.81% in the last 12 months. Over the past 10 years, Arcutis Biotherapeutics, Inc. had an annualized return of -21.39%, while the S&P 500 had an annualized return of 6.84%, indicating that Arcutis Biotherapeutics, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
1 month-36.77%-0.66%
Year-To-Date-30.88%3.42%
6 months-44.58%5.67%
1 year-41.81%-10.89%
5 years (annualized)-21.39%6.84%
10 years (annualized)-21.39%6.84%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202311.96%-2.35%
2022-29.09%-7.48%-2.55%-14.10%

Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Arcutis Biotherapeutics, Inc. Sharpe ratio is -0.67. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.


-0.80-0.60-0.40-0.200.000.20NovemberDecember2023FebruaryMarch
-0.67
-0.47
ARQT (Arcutis Biotherapeutics, Inc.)
Benchmark (^GSPC)

Dividend History


Arcutis Biotherapeutics, Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%NovemberDecember2023FebruaryMarch
-72.34%
-17.21%
ARQT (Arcutis Biotherapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Arcutis Biotherapeutics, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Arcutis Biotherapeutics, Inc. is 72.34%, recorded on Mar 24, 2023. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-72.34%Feb 9, 2021535Mar 24, 2023
-51.71%Mar 24, 2020155Oct 30, 202067Feb 8, 2021222
-39.4%Mar 11, 20206Mar 18, 20202Mar 20, 20208
-6.89%Feb 27, 20202Feb 28, 20207Mar 10, 20209
-4.64%Feb 25, 20201Feb 25, 20201Feb 26, 20202
-3.77%Feb 11, 20205Feb 18, 20201Feb 19, 20206
-3.51%Feb 5, 20202Feb 6, 20201Feb 7, 20203

Volatility Chart

Current Arcutis Biotherapeutics, Inc. volatility is 50.56%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


10.00%20.00%30.00%40.00%50.00%60.00%70.00%NovemberDecember2023FebruaryMarch
50.56%
19.50%
ARQT (Arcutis Biotherapeutics, Inc.)
Benchmark (^GSPC)